Can Previous Chemotherapy Affect the Outcome of Nivolumab
Treatment in Non-small Cell Lung Cancer?

J 2022

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR et. al.

Základní údaje

Originální název

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Autoři

SVATON, Martin (203 Česká republika, garant), Monika BRATOVÁ (203 Česká republika, domácí), Leona KOUBKOVA, Ondrej FISCHER (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Michal HRNCIARIK (203 Česká republika), Daniel DOLEZAL (203 Česká republika), Ondrej BILEK (203 Česká republika), Jana KREJCI (203 Česká republika), Marie DROSSLEROVA (203 Česká republika), Zdenka DLOUHA (203 Česká republika), Jiri BLAZEK (203 Česká republika), Petra MAJKOVA (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí) a Marek STASTNY (203 Česká republika)

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2022, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.000

Kód RIV

RIV/00216224:14110/22:00126148

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/anticanres.15677

UT WoS

000778640800010

Klíčová slova anglicky

NSCLC; lung cancer; nivolumab; chemotherapy; overall survival; pemetrexed; taxanes; vinorelbine

Štítky

14110215, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 4. 2023 09:11, Mgr. Tereza Miškechová

Anotace

V originále

Aim: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). Results: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. Conclusion: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexedbased one.

Citovat

SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR, Michal HRNCIARIK, Daniel DOLEZAL, Ondrej BILEK, Jana KREJCI, Marie DROSSLEROVA, Zdenka DLOUHA, Jiri BLAZEK, Petra MAJKOVA, Lucie BROŽOVÁ a Marek STASTNY. Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? Anticancer Research. Athens: International Institute of Anticancer Research, 2022, roč. 42, č. 4, s. 1987-1995. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.15677.

@article{1863072,
   author = {Svaton, Martin and Bratová, Monika and Koubkova, Leona and Fischer, Ondrej and Melichar, Bohuslav and Hrnciarik, Michal and Dolezal, Daniel and Bilek, Ondrej and Krejci, Jana and Drosslerova, Marie and Dlouha, Zdenka and Blazek, Jiri and Majkova, Petra and Brožová, Lucie and Stastny, Marek},
   article_location = {Athens},
   article_number = {4},
   doi = {http://dx.doi.org/10.21873/anticanres.15677},
   keywords = {NSCLC; lung cancer; nivolumab; chemotherapy; overall survival; pemetrexed; taxanes; vinorelbine},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?},
   url = {https://ar.iiarjournals.org/content/42/4/1987},
   volume = {42},
   year = {2022}
}

TY  - JOUR
ID  - 1863072
AU  - Svaton, Martin - Bratová, Monika - Koubkova, Leona - Fischer, Ondrej - Melichar, Bohuslav - Hrnciarik, Michal - Dolezal, Daniel - Bilek, Ondrej - Krejci, Jana - Drosslerova, Marie - Dlouha, Zdenka - Blazek, Jiri - Majkova, Petra - Brožová, Lucie - Stastny, Marek
PY  - 2022
TI  - Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
JF  - Anticancer Research
VL  - 42
IS  - 4
SP  - 1987-1995
EP  - 1987-1995
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - NSCLC
KW  - lung cancer
KW  - nivolumab
KW  - chemotherapy
KW  - overall survival
KW  - pemetrexed
KW  - taxanes
KW  - vinorelbine
UR  - https://ar.iiarjournals.org/content/42/4/1987
N2  - Aim: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). Results: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. Conclusion: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexedbased one.
ER  -

SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR, Michal HRNCIARIK, Daniel DOLEZAL, Ondrej BILEK, Jana KREJCI, Marie DROSSLEROVA, Zdenka DLOUHA, Jiri BLAZEK, Petra MAJKOVA, Lucie BROŽOVÁ a Marek STASTNY. Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2022, roč.~42, č.~4, s.~1987-1995. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.15677.

Podrobný výpis o publikaci